Purpose: To provide data on the prevalence of ocular hypertension and glaucoma and on the diagnostic validity of tonometry. Methods: In this cross-sectional, population-based study, 4,927 subjects over 40 years of age were examined. Each subject underwent a complete ocular examination as part of the Egna-Neumarkt Glaucoma Study. These examinations were carried out by trained, quality-controlled ophthalmologists, according to a predetermined standard protocol that included a medical interview, applanation tonometry, computerized perimetry, optic nerve head examination and other ocular measurements. The following data were recorded: mean IOP, prevalence of ocular hypertension, primary open-angle glaucoma and normal tension glaucoma. Sensitivity, specificity and the predictive value of the tonometric test, as well as the distribution of IOP in the different groups were also determined. Results: The overall prevalence of ocular hypertension, hypertensive primary open-angle glaucoma and normal tension glaucoma corresponded to 2.1, 1.4 and 0.6%, respectively. Other types of glaucoma accounted for a further 0.9%. The sensitivity and specificity of the tonometric test in recognizing glaucoma (cut-off between 21 and 22 mm Hg) were, respectively, 80.1 and 97.8%. The predictive values of the positivity and negativity of the test were 52.1 and 99.4%, respectively. Conclusions: The prevalence of ocular hypertension and glaucoma was similar to that found in several recent epidemiological studies. Tonometry alone is obviously not sufficient to ascertain or to exclude the presence of glaucoma; its diagnostic validity however is high and should never be underestimated. An elevated IOP is the main risk factor for glaucoma, with the degree of risk increasing as the level of IOP increases.

Keywords:
Intraocular pressure, Primary open-angle glaucoma, Normal tension glaucoma, Glaucoma, epidemiology
1.
Stromberg U: Ocular hypertension. Frequency, course and relation to other disorders occurring in glaucoma, as seen from mass survey of all inhabitants over forty years of age in a Swedish town. Acta Ophthalmol 1962;69(suppl):7–75.
2.
Hollows FC, Graham PA: Intraocular pressure, glaucoma and glaucoma suspects in a defined population. Br J Ophthalmol 1966;50:570–586.
3.
Leibowitz HM, Krueger DE, Maunder LR, Milton RC, Kini MM, Kahn HA, Nickerson RJ, Pool J, Colton TL, Ganley JP, Loewenstein JI, Dawber TR: The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration and visual acuity in a general population of 2631 adults, 1973–1975. Surv Ophthalmol 1980;24(suppl):335–610.
4.
Bengtsson B: The prevalence of glaucoma. Br J Ophthalmol 1981;65:46–49.
5.
Armaly MF: The distribution of applanation pressure and arcuate scotoma; in Paterson G, Miller SH, Paterson GD (eds). Drug Mechanisms in Glaucoma. Boston, Little Brown, 1966.
6.
Kahn HA, Milton RC: Alternative definitions of open angle glaucoma: Effect on prevalence and associations in the Framingham Eye Study. Arch Ophthalmol 1980;98:2172–2177.
7.
Mason RP, Kosoko O, Wilson MR, Martone JF, Cowan CL Jr, Gear JC, Ross-Degnan D: National survey of prevalence and risk factors of glaucoma in St. Lucia, West Indies. Ophthalmology 1989;96:1363–1368.
8.
Tielsch JM, Katz J, Singh K, Quigley HA, Gottsch JD, Javitt J, Sommer A: A population-based evaluation of glaucoma screening. The Baltimore Eye Survey. Am J Epidemiol 1991;134:1102–1110.
9.
Klein BEK, Klein R, Sponsel WE, Franke T, Cantor LB, Martone J, Menage MJ: Prevalence of glaucoma. The Beaver Dam Eye Study. Ophthalmology 1992;99:1499–1504.
10.
Dielemans I, Vingerling JR, Wolfs RCW, Hofman A, Grobbee DE, De Jong PTVM: The prevalence of primary open-angle glaucoma in a population-based study in the Netherlands. The Rotterdam Study Ophthalmology 1994;101:1851–1855.
11.
Quertani A, Zhioua R, Trabelsi A, Jrad J: Prévalence du glaucome chronique à angle ouvert dans une commune de Tunis. J Fr Ophtalmol 1955;18:178–182.
12.
Giuffré G, Giammanco R, Dardanoni G, Ponte F: Prevalence of glaucoma and distribution of intraocular pressure in a population. The Casteldaccia Eye Study. Acta Ophthalmol Scand 1995;73:222–225.
13.
Ekström C: Prevalence of open-angle glaucoma in central Sweden. Acta Ophthalmol Scand 1996;74:107–112.
14.
Mitchell P, Smith W, Attebo K, Healey PR: Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study. Ophthalmology 1996;103:1661–1669.
15.
Shiose Y: Method for glaucoma screening in a multicenter collaborative study in Japan. Chibret Int J Ophthalmol 1990;7:42–49.
16.
Bonomi L, Marchini G, Marraffa M, Bernardi P, De Franco I, Perfetti S, Varotto A, Tenna V: Prevalence of glaucoma and intraocular pressure distribution in a defined population. The Egna-Neumarkt Study. Ophthalmology 1998;105:209–215.
17.
Davanger M, Ringvold A, Blika S: The probability of having glaucoma at different IOP levels. Acta Ophthalmol Scand 1991;69:565–568.
18.
Leske MC, Connell AMS, Wu SY, Hyman L, Schachat AP: Distribution of intraocular pressure. The Barbados Eye Study. Arch Ophthalmol 1997;115:1051–1057.
© 2001 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.